Heterogeneity, urgency, generalizability, and enrollment
The HUGE balance in ALS trials
Citation Manager Formats
Make Comment
See Comments

Article Information
- First Published January 9, 2019.
Article Versions
- Previous version (January 9, 2019 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Chafic Karam, MD and
- James D. Berry, MD, MPH
- Chafic Karam, MD and
I serve on DMSB for a Phase 2/3 Trial of Arimoclomol in Inclusion Body Myositis (IBM)
NONE
I have received speaker honoraria from Akcea, Alnylam, Alexion and CSL behring.
I served on the editorial board of the Neurology Resident and Fellow section. I served as Deputy Editor, Neurology Write Click, Dispute and Debate.
NONE
NONE
NONE
I have received consulting honoraria from Akcea, Alnylam, Alexion, Biogen, Cytokinetics, Genzyme and CSL Behring.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- James D. Berry, MD, MPH
(1) MT Pharma (commercial entity) - attended one-day scientific advisory meeting (2) Denali Therapeutics (commercial entity) - attended one-day scientific advisory meeting (3) Orion Corporation (commercial entity) - attended one- day scientific advisory meeting (4) Anelixis Therapeutics (commercial entity) - advisor to company (5) Mayo Clinic (non-profit entity) - DSMB member for ALS stem cell trial
NONE
(1) ALS Association (non-profit entity) - reimbursed for travel to ALS patient symposium (2) MDA (non-profit entity) - reimbursed for travel to scientific conference (3) ALS One (non-profit entity) - reimbursed for travel to ALS advocacy meeting (4) ALS Finding a Cure (non-profit entity) - reimbursed for travel to ALS research meetings
Wife (Ann Shinn) - Neuropsychopharmacology - Editorial Board Member
MicroRNAs in neurodegenerative disorders (WO2013055865)
NONE
NONE
NONE
NONE
NONE
NONE
(1) Voyager Therapeutics - Commercial Entity - Fellowship Funding (2) Neuraltus Pharmaceuticals - Commercial entity - Site Investigator for Trial (3) Cytokinetics - Commercial entity - Site Investigator for Trial (4) Brainstorm Cell Therapeutics - Commercial entity - Site Investigator for Trial (5) Amylyx Pharmaceuticals - Commercial entity - Site Investigator for Trial (6)
(1) NIH/NINDS (PI: Steven M. Greenberg) Co-Investigator, 2011-2018 (2) NIH R01DC013547 (PI: Jordan Green) Co-PI, 2014-2019 (3) NIH/NINDS R21 NS101673 (PI: Butovsky) Co-PI, 2017-2019 (4) NIH/NINDS R21 NS104609 (PI: Butovsky) Co-PI, 2018-2020 (5) NIH-R01 DC017291 (PIs: Green and Yunusova) Co-I, 2018- 2023
NONE
(1) Muscular Dystrophy Association (2) ALS Finding a Cure (3) ALS Association (4) ALS One
NONE
NONE
MicroRNAs in neurodegenerative disorders (WO2013055865) - Licensing royalty
NONE
NONE
NONE
- From the Department of Neurology (C.K.), Oregon Health & Science University, Portland; and Department of Neurology (J.D.B.), Massachusetts General Hospital, Boston.
- Correspondence
Dr. Karam chafickaram{at}gmail.com
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.